Amalgamated Bank Sells 2,140 Shares of LivaNova PLC (NASDAQ:LIVN)

Amalgamated Bank cut its holdings in LivaNova PLC (NASDAQ:LIVN) by 8.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,171 shares of the company’s stock after selling 2,140 shares during the quarter. Amalgamated Bank’s holdings in LivaNova were worth $1,270,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. ProShare Advisors LLC increased its stake in LivaNova by 4.7% in the 1st quarter. ProShare Advisors LLC now owns 12,378 shares of the company’s stock valued at $692,000 after buying an additional 561 shares during the last quarter. Entropy Technologies LP acquired a new position in LivaNova during the first quarter worth $295,000. State Board of Administration of Florida Retirement System raised its holdings in shares of LivaNova by 13.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 17,542 shares of the company’s stock valued at $981,000 after purchasing an additional 2,060 shares during the last quarter. Vanguard Group Inc. grew its position in LivaNova by 3.5% during the first quarter. Vanguard Group Inc. now owns 1,832,987 shares of the company’s stock valued at $102,537,000 after buying an additional 62,480 shares during the period. Finally, Acadian Asset Management LLC bought a new position in LivaNova during the first quarter worth about $94,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Performance

LIVN stock opened at $53.58 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The business has a 50-day moving average price of $51.47 and a 200 day moving average price of $52.98. The company has a market capitalization of $2.91 billion, a P/E ratio of 128.86 and a beta of 1.01. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on LIVN shares. Mizuho lowered their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. The Goldman Sachs Group began coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Baird R W raised shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Stifel Nicolaus increased their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Tuesday. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, LivaNova has an average rating of “Buy” and an average target price of $69.17.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.